Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolent Health, Inc. (NYSE: EVH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Evolent’s specialty care business, capital structure, governance and material events affecting the company.
Through its 8-K filings, Evolent reports results of operations and financial condition, such as quarterly earnings releases that include revenue and adjusted EBITDA, explanations of non-GAAP financial measures and management’s discussion of demand for complex specialty care solutions. Other 8-Ks describe capital markets and financing activities, including the issuance of 4.50% convertible senior notes due 2031, the related indenture terms, and the use of proceeds to repurchase 1.50% convertible senior notes due 2025 and shares of Class A common stock. Amendments to credit agreements and commitment letters for incremental facilities are also disclosed, outlining available debt capital and key conditions.
Evolent’s filings further cover strategic transactions, such as the stock purchase agreement to sell its value-based primary care business, Evolent Care Partners, to Privia Management Company, LLC, and subsequent filings noting consummation of that transaction. Governance and leadership changes are documented under Item 5.02 of Form 8-K, detailing appointments and transitions in executive roles, including the Chief Financial Officer, as well as board retirements and new independent director appointments and related compensation and indemnification arrangements.
Regulatory and legal matters appear in filings as well. For example, Evolent has disclosed receiving a Civil Investigative Demand from the Department of Justice in connection with a False Claims Act investigation related to a former customer and Medicare Advantage diagnosis codes, and has stated that it is cooperating with the government.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of earnings releases, financing agreements, strategic transactions, leadership changes and legal disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks and other forms are available promptly, while structured access to information on insider and executive arrangements can support deeper analysis of Evolent’s corporate governance and compensation practices.
Evolent Health Inc: The Vanguard Group filed an Amendment No. 8 to a Schedule 13G/A reporting that, following an internal realignment, certain Vanguard subsidiaries will report disaggregated holdings and that Vanguard's reported beneficial ownership of Evolent Health common stock is 0 shares (0%) as reflected in the filing dated 03/13/2026 and signed 03/26/2026.
Evolent Health, Inc. CEO Seth Blackley reported equity award activity and related tax-withholding transactions. He received a grant of 1,425,310 performance-based share units at a price of $0.00 per unit and acquired 58,921 shares of Class A Common Stock upon settlement of earlier performance-based units.
To cover tax obligations tied to these vesting and settlement events, a total of 24,053, 17,736, and 9,537 shares of Class A Common Stock were withheld at per-share prices of $3.51, $3.58, and $3.25, respectively. After these transactions, Blackley directly owned 836,962 shares of Class A Common Stock and 1,425,310 performance-based share units, with the new PSUs eligible to be earned from March 1, 2027 to February 28, 2029 based on stock price and service conditions.
Evolent Health, Inc. General Counsel Jonathan Weinberg reported several equity compensation transactions involving the company’s Class A Common Stock and performance-based share units. On March 2, 2026, he received a grant of 179,661 performance-based share units at no cash cost and a separate award of 4,910 shares of Class A Common Stock.
On the same date, 1,896 shares were withheld at prices of $3.58 per share to cover tax obligations, and on March 1, 2026, an additional 4,406 shares were withheld at $3.25 per share for tax withholding. On March 3, 2026, a further 8,275 shares were withheld at $3.51 per share for tax liabilities. These “F” coded transactions reflect tax-withholding dispositions, not open-market sales, and left Weinberg with 244,512 shares of Class A Common Stock held directly.
Footnotes explain that some shares were delivered upon settlement of earlier performance-based awards after achievement of specified performance metrics, and the new PSUs may be earned between March 1, 2027 and February 28, 2029 based on stock price and service conditions, with potential payout from 0% to 250% of target.
Evolent Health president Daniel McCarthy reported a mix of equity grants and tax-related share withholdings. He received 826,440 performance-based share units at target under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan, which may be earned based on specified stock price performance conditions from March 1, 2027 to February 28, 2029, subject to service conditions.
McCarthy also acquired 39,281 shares of Class A common stock upon settlement of a prior performance-based share unit award that vested at the end of 2025 after performance certification on March 2, 2026. To satisfy tax withholding obligations on vested restricted stock units and settled PSUs, 24,027, 18,192 and 7,811 Class A shares were withheld at prices between $3.25 and $3.58 per share. Following these transactions, he directly owned 423,022 Class A shares.
Evolent Health Chief Accounting Officer Shams Aammaad reported equity compensation activity and related tax withholding transactions. He received a grant of 55,173 performance-based share units (PSUs) and 1,686 shares of Class A Common Stock as awards. In separate moves, a total of 4,311, 850 and 2,577 Class A shares were withheld to cover tax obligations upon vesting and settlement of prior awards, described as tax-withholding dispositions rather than open-market sales. The new PSUs can be earned based on stock price performance conditions measured from March 1, 2027 to February 28, 2029, with potential payout from 0% to 250% of the target level, subject to service-based conditions.
Ramos Mario reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. Chief Financial Officer Mario Ramos received a grant of 429,041 performance-based share units (PSUs) at a price of $0.00 per unit. The PSUs are granted under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan and may be earned based on stock price performance between March 1, 2027 and February 28, 2029, subject to service-based conditions. Each PSU is currently shown at a target level, and the final number earned can range from 0% to 250% of this target after the performance period.
Evolent Health, Inc. reports on its value-based healthcare services business, which focuses on managing complex specialty care such as oncology, cardiology and musculoskeletal conditions for health plans and other risk-bearing entities. The company designs evidence-based clinical pathways, builds high-performance provider networks and uses proprietary technology platforms, including Identifi®, to support clinical decisions and administrative services.
Revenue comes mainly from per-member-per-month fees under specialty care management and administrative services contracts, with some performance-based and capitated arrangements where Evolent shares financial risk for medical costs. The company highlights reliance on a few large partners, growing use of risk-sharing contracts, regulatory exposure in Medicare and Medicaid, and extensive fraud, privacy, AI and data-security compliance requirements as key risks.
Evolent Health reported weaker 2025 GAAP results but stable adjusted profitability and set cautious 2026 targets. Full-year 2025 revenue was $1.88 billion, down from $2.55 billion in 2024, while net loss widened to $579.4 million with a net loss margin of 30.9%.
Results were heavily impacted by a $398 million goodwill impairment, a $52.5 million loss on option exercise and refinancing-related charges. By contrast, adjusted EBITDA was $151.2 million with an 8.1% margin, up from a 6.3% margin in 2024, and adjusted income attributable to common shareholders was $10.4 million.
Management forecast 2026 revenue of $2.4–$2.6 billion and adjusted EBITDA of $110–$140 million, implying strong top-line growth but lower adjusted EBITDA than 2025 as new Performance Suite contracts and health-plan membership shifts pressure margins early in the year.
Evolent Health, Inc. received an amended ownership report from Eventide Asset Management, LLC and individuals Finny Kuruvilla and Robin C. John. They report beneficial ownership of 1,713 shares of Class A common stock, representing 0.0% of the class as of 12/31/2025.
Eventide holds sole voting and dispositive power over the 1,713 shares, while Kuruvilla and John share voting and dispositive power over the same shares. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of influencing control of Evolent Health.
Morgan Stanley has updated its ownership disclosure in Evolent Health, Inc. through an amended Schedule 13G. As of the event date of 12/31/2025, Morgan Stanley reports beneficial ownership of 9,097,808 shares of Evolent’s Class A common stock, representing 8.1% of the class. Its affiliate Morgan Stanley Capital Services LLC reports beneficial ownership of 7,380,233 shares, or 6.6% of the class.
The firms report shared voting and dispositive power over these shares and confirm the holdings were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Evolent Health. Certain other Morgan Stanley units with disaggregated reporting are expressly excluded from this disclosure.